Brokerages Set Benitec Biopharma Limited (NASDAQ:BNTC) PT at $26.00

Key Points

• Benitec Biopharma Limited (NASDAQ:BNTC) has received an average rating of "Buy" from eight analysts, with one assigning a "strong buy" rating and a consensus price target of $26.00.
• The company's recent earnings report showed that it beat expectations by posting an earnings per share (EPS) of ($0.24), surpassing the consensus estimate of ($0.36) by $0.12.
• Benitec Biopharma has seen significant institutional investment, with Geode Capital Management increasing its stake by 134.7% in the fourth quarter, indicating growing confidence in the company.

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has received an average rating of "Buy" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $26.00.

A number of research firms recently commented on BNTC. HC Wainwright restated a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a research report on Monday, May 19th. TD Cowen initiated coverage on Benitec Biopharma in a research report on Monday, July 7th. They issued a "buy" rating on the stock. Finally, JMP Securities reiterated a "market outperform" rating and issued a $20.00 price objective on shares of Benitec Biopharma in a research report on Thursday, May 15th.

Benitec Biopharma Price Performance

NASDAQ BNTC traded up $0.08 during trading hours on Tuesday, reaching $12.59. 19,183 shares of the company's stock were exchanged, compared to its average volume of 70,782. The stock has a market cap of $330.54 million, a PE ratio of -8.34 and a beta of 0.40. Benitec Biopharma has a one year low of $8.06 and a one year high of $17.15. The firm has a fifty day moving average of $13.04 and a 200-day moving average of $13.04. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. On average, equities research analysts predict that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BNTC. Geode Capital Management LLC lifted its stake in shares of Benitec Biopharma by 134.7% in the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock valued at $2,490,000 after purchasing an additional 113,109 shares during the period. MYDA Advisors LLC acquired a new position in shares of Benitec Biopharma in the 4th quarter valued at $632,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Benitec Biopharma by 134.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after purchasing an additional 1,131,129 shares during the period. Northern Trust Corp lifted its stake in shares of Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares during the period. Finally, 683 Capital Management LLC acquired a new position in shares of Benitec Biopharma in the 4th quarter valued at $452,000. Institutional investors and hedge funds own 52.19% of the company's stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.